These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 27852694)

  • 1. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease.
    Yang F; Hellyer JA; Than C; Ullal AJ; Kaiser DW; Heidenreich PA; Hoang DD; Winkelmayer WC; Schmitt S; Frayne SM; Phibbs CS; Turakhia MP
    Heart; 2017 Jun; 103(11):818-826. PubMed ID: 27852694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
    Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
    Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study).
    Yong C; Azarbal F; Abnousi F; Heidenreich PA; Schmitt S; Fan J; Than CT; Ullal AJ; Yang F; Phibbs CS; Frayne SM; Ho PM; Shore S; Mahaffey KW; Turakhia MP
    Am J Cardiol; 2016 Jan; 117(1):61-8. PubMed ID: 26552504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.
    Urbonas G; Valius L; Šakalytė G; Petniūnas K; Petniūnienė I
    Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30650565
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease.
    Batra G; Modica A; Renlund H; Larsson A; Christersson C; Held C
    Open Heart; 2022 Sep; 9(2):. PubMed ID: 36104096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
    Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia.
    Jacobs V; Woller SC; Stevens S; May HT; Bair TL; Anderson JL; Crandall BG; Day JD; Johanning K; Long Y; Mallender C; Olson JL; Osborn JS; Weiss JP; Bunch TJ
    Heart Rhythm; 2014 Dec; 11(12):2206-13. PubMed ID: 25111326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.
    Liu S; Singer A; McAlister FA; Peeler W; Heran BS; Drummond N; Manca DP; Allan GM; Korownyk C; Kolber MR; Greiver M; Garrison SR
    Can Fam Physician; 2019 Jun; 65(6):416-425. PubMed ID: 31189630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials.
    Proietti M; Lane DA; Lip GYH
    EBioMedicine; 2016 Jun; 8():309-316. PubMed ID: 27428440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
    Liu S; Li X; Shi Q; Hamilton M; Friend K; Zhao Y; Horblyuk R; Hede S; Shi L
    Curr Med Res Opin; 2018 Mar; 34(3):415-421. PubMed ID: 28945114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
    Williams BA; Evans MA; Honushefsky AM; Berger PB
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.
    Apostolakis S; Sullivan RM; Olshansky B; Lip GYH
    Chest; 2013 Nov; 144(5):1555-1563. PubMed ID: 23669885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3 - 5 chronic kidney disease and nonvalvular atrial fibrillation: a 12-year follow-up study.
    Chiu PF; Huang CH; Liou HH; Wu CL; Chang C; Chang CC; Chang HR
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):504-8. PubMed ID: 24755133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.